Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

ClinicalTrials.gov ID: NCT01338987

Public ClinicalTrials.gov record NCT01338987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation

Study identification

NCT ID
NCT01338987
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
76 participants

Conditions and interventions

Interventions

  • First Allogeneic Bone Marrow Transplant (BMT) Procedure
  • Leuprolide Drug
  • 18F FLT Drug
  • Cyclophosphamide Drug
  • Methotrexate Drug
  • Tacrolimus Drug
  • Total Body Irradiation Radiation
  • Busulfan Drug
  • Fludarabine Drug
  • Second Allogeneic Bone Marrow Transplantation Procedure

Procedure · Drug · Radiation

Eligibility (public fields only)

Age range
4 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 18, 2011
Primary completion
Nov 30, 2017
Completion
Nov 18, 2020
Last update posted
Mar 17, 2021

2011 – 2020

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Childrens National Medical Center Washington D.C. District of Columbia 20010
National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland 20892
University of Oklahoma Oklahoma City Oklahoma 73104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01338987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 17, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01338987 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →